Stock analysts at Cantor Fitzgerald assumed coverage on shares of Codexis (NASDAQ:CDXS – Get Free Report) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set an “overweight” rating and a $11.00 price target on the biotechnology company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 225.44% from the stock’s […]
Stock analysts at Redburn Atlantic began coverage on shares of Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) in a report issued on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $60.00 price target on the medical device company’s stock. Redburn Atlantic’s target price suggests a potential upside of 17.12% from the […]
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has been given a consensus recommendation of “Buy” by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have updated their coverage on the stock […]
Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has earned an average rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the […]
Baird R W upgraded shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) to a strong-buy rating in a research report released on Wednesday morning, Zacks.com reports. Several other equities research analysts have also commented on MNMD. SVB Leerink started coverage on shares of Mind Medicine (MindMed) in a research note on Monday, April 15th. […]